Covid-19 vaccines have raised concerns about shots that are key to inoculation rollouts from Brazil to Indonesia, especially after their efficacy was questioned by one of the most senior Chinese health officials.Bloomberg spoke to two experts about the vaccines, zeroing in on the Sinovac Biotech Ltd.
shot, which has been the focus of a crisis in confidence after it posted efficacy levels of just above 50% in a final stage trial in Brazil -- the minimum level required by leading global drug regulators.
Other Chinese immunizations have delivered rates from 66% to 79%, still far behind the shots developed by Pfizer Inc., Moderna Inc.